Pfizer hoping for earlier Elrexfio use in RRMM after Phase III trial

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

Pfizer's blood cancer drug meets main goal in late-stage trial

April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in ‌a late-stage trial that tested the blood ...

Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio

Pfizer (PFE) announced on Wednesday that Elrexfio, a treatment for a type of blood cancer called multiple myeloma, reached the primary endpoint in a late-stage trial, raising prospects for the ...
Fierce Pharma

Pfizer looks to jump start Elrexfio with topline win in second-line myeloma

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
Hosted on MSN

Pfizer’s Elrexfio shows strong late-stage trial results in myeloma

Pfizer’s multiple myeloma drug Elrexfio met its main goal in a late-stage trial, delivering a statistically significant and clinically meaningful improvement in progression-free survival over standard ...